Category: Clinical Breakthroughs
-
Without Coronary Calcium, Risk Factors Impact Cardiovascular Disease
Among patients with no detectable coronary artery calcium, those who smoke, have diabetes or hypertension have the highest risk of cardiovascular disease events, according to a recent study.
-
In Cancer Treatment, Quality of Life Matters More and More
A Northwestern Medicine study has found that a new combination immune therapy treatment not only extended cancer patients’ lives better than other treatments, it also was less toxic to their overall health than other drugs on the market.
-
Improving Pre-Surgical Workups for Epilepsy
Using MRI, EEG and clinical characteristics, the pre-surgical workup can predict if patients with epilepsy will benefit from a more invasive examination.
-
Genomic Variant May Predict Cardiotoxicity From Chemotherapy
A team of investigators have discovered a novel genomic variant that may help clinicians predict which patients will experience cardiotoxicity from a widely used chemotherapy drug, according to a Northwestern Medicine study.
-
First Model to Predict Lifetime Risk of Heart Failure
A new Northwestern Medicine study has, for the first time, derived and validated a set of risk prediction models for lifetime risk of heart failure.
-
Microspheres Delay Progression of Colon Cancer
A recent study showed that targeted radioembolization alongside chemotherapy improved progress-free survival for patients with metastatic colon cancer.
-
Effectiveness of Subcutaneous Defibrillators
Electric shocks delivered by subcutaneous defibrillators are equally effective compared to shocks delivered by conventional transvenous defibrillators, according to a recent study.
-
Statins Cost-Effective in Young Adults
Statin therapy has been shown cost-effective for lowering cholesterol in young adults, according to a study published in the Journal of the American College of Cardiology.
-
Predicting Which Glioblastoma Patients Will Respond to Immunotherapy
Northwestern Medicine scientists have discovered a new biomarker to identify which patients with brain tumors called glioblastomas — the most common and malignant of primary brain tumors — might benefit from immunotherapy.
-
Drug May Benefit Patients with Heart Failure
Dapagliflozin, a drug commonly used to treat type 2 diabetes, improved heart failure-related symptoms and physical limitations in patients with heart failure with preserved ejection fraction.
